 high-dos cisplatin dacarbazin treatment metastat melanoma combin cisplatin dacarbazin dtic activ metastat melanoma respons rate regimen phase II studi dose intens cisplatin twenty-two patient patient cisplatin day dtic day excess toxic protocol cisplatin day dtic day day regimen overal respons rate partial complet respons CR median durat respons month CR sustain unmaintain remiss excess year patient regimen high-dos cisplatin dtic schedul effect well-toler therapi metastat melanoma